These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35570147)

  • 1. Re: Longbin Xiong, Jane K. Nguyen, Yulu Peng, et al. What Happens to the Preserved Renal Parenchyma After Clamped Partial Nephrectomy? Eur Urol. 2022;81:492-500. https://doi.org/10.1016/j.eururo.2021.12.036.
    Ren S; Zhong S; Fan S; Li X; Zhou F; Wang D
    Eur Urol; 2022 Aug; 82(2):e49. PubMed ID: 35570147
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?
    Mollica V; Rizzo A; Massari F
    Eur Urol Oncol; 2020 Aug; 3(4):559-560. PubMed ID: 32553708
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018: The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition.
    Singla N; Margulis V
    Eur Urol; 2020 Aug; 78(2):e79-e80. PubMed ID: 32362497
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Nirmish Singla and Vitaly Margulis's Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition: Nephrectomy After Immunotherapy: The Duration of Treatment Exposure is Probably Decisive.
    Pignot G; Thiery-Vuillemin A; Walz J; Bigot P; Bensalah K; Gravis G; Barthélémy P
    Eur Urol; 2020 Aug; 78(2):e81-e82. PubMed ID: 32389444
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Shun Wan, Kun-peng Li, and Li Yang's Letter to the Editor re: Jordan M. Rich, Kennedy E. Okhawere, Charles Nguyen, et al. Transperitoneal Versus Retroperitoneal Single-port Robotic-assisted Partial Nephrectomy: An Analysis from the Single Port Advanced Research Consortium. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.06.004.
    Rich JM; Okhawere KE; Razdan S; Badani KK
    Eur Urol Focus; 2024 May; 10(3):495-496. PubMed ID: 37739915
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Börje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.006.
    Wei Y; Zhang R; Lin L
    Eur Urol; 2022 Sep; 82(3):e88. PubMed ID: 35750581
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Jordan M. Rich, Kennedy E. Okhawere, Charles Nguyen, et al. Transperitoneal Versus Retroperitoneal Single-port Robotic-assisted Partial Nephrectomy: An Analysis from the Single Port Advanced Research Consortium. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.06.004.
    Wan S; Li KP; Yang L
    Eur Urol Focus; 2024 May; 10(3):493-494. PubMed ID: 37722953
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Mengda Zhang and Long Wang's Letter to the Editor re: Francesco Porpiglia, Enrico Checcucci, Daniele Amparore, et al. Three-dimensional Augmented Reality Robot-assisted Partial Nephrectomy in Case of Complex Tumours (PADUA ≥ 10): A New Intraoperative Tool Overcoming the Ultrasound Guidance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.11.024.
    Amparore D; Checcucci E; Fiori C; Porpiglia F
    Eur Urol; 2020 Jun; 77(6):e163-e164. PubMed ID: 32279902
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034.
    Patel HD; Allaf ME
    Eur Urol; 2013 Nov; 64(5):e105-6. PubMed ID: 23910939
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Hiten D. Patel and Mohamad E. Allaf's letter to the editor re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034.
    Sun M; Karakiewicz PI; Trinh QD
    Eur Urol; 2013 Nov; 64(5):e107-8. PubMed ID: 23910940
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Andrea Mari, Riccardo Tellini, Francesco Porpiglia, et al. Perioperative and Mid-term Oncological and Functional Outcomes After Partial Nephrectomy for Complex (PADUA Score ≥10) Renal Tumors: A Prospective Multicenter Observational Study (the RECORD2 Project). Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2020.07.004.
    Grivas N; Goonewardene S; Everaerts W; Kalampokis N;
    Eur Urol Focus; 2021 Sep; 7(5):1210-1211. PubMed ID: 33358885
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Julia Dagnæs-Hansen, Gitte Hjartbro Kristensen, Hein V. Stroomberg, Søren Schwartz Sørensen, Martin Andreas Røder. Surgical Approaches and Outcomes in Living Donor Nephrectomy: A Systematic Review and Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2022.03.021.
    Pecoraro A; Li Marzi V; Serni S; Campi R
    Eur Urol Focus; 2023 Jan; 9(1):216-217. PubMed ID: 35798648
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting Functional Outcomes After Partial and Radical Nephrectomy. Eur Urol 2019;75:766-72: Partial Nephrectomy: "Geocentrism" of the 21st century in the Church of Urology?
    Takahashi T
    Eur Urol; 2019 Sep; 76(3):e65-e66. PubMed ID: 31164251
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Francesco Porpiglia, Enrico Checcucci, Daniele Amparore, et al. Three-dimensional Augmented Reality Robot-assisted Partial Nephrectomy in Case of Complex Tumours (PADUA ≥ 10): A New Intraoperative Tool Overcoming the Ultrasound Guidance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.11.024.
    Zhang M; Wang L
    Eur Urol; 2020 Jun; 77(6):e161-e162. PubMed ID: 32303382
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Oscar Reig Torras, Akhilesh Mishra, Alana Christie, et al. Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.003.
    Wang Z; Zhao Y; Zhang Y
    Eur Urol; 2022 May; 81(5):e120. PubMed ID: 35232603
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Nikolaos Grivas, Sanchia Goonewardene, Wouter Everaerts, Nikolaos Kalampokis's Letter to the Editor re: Andrea Mari, Riccardo Tellini, Francesco Porpiglia, et al. Perioperative and Mid-term Oncological and Functional Outcomes After Partial Nephrectomy for Complex (PADUA Score ≥10) Renal Tumors: A Prospective Multicenter Observational Study (the RECORD2, Project). Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2020.07.004.
    Mari A; Tellini R; Ficarra V; Carini M; Minervini A;
    Eur Urol Focus; 2021 Sep; 7(5):1212-1213. PubMed ID: 33384273
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Robert J. Motzer, Pratik P. Rane, Todd L. Saretsky, et al. Patient-reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic Literature Review. Eur Urol. Eur Urol. 2023;84:406-17.
    Gutiérrez Rojas AF; Fernández D; Diaz Ritter C
    Eur Urol; 2024 Mar; 85(3):e94. PubMed ID: 37802682
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006: Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?
    Noel J; Huillard O; Goldwasser F
    Eur Urol; 2021 Apr; 79(4):e112. PubMed ID: 33518379
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Carlo Bravi, Emily Vertosick, Nicole Benfante, et al. Impact of Acute Kidney Injury and Its Duration on Long-term Renal Function After Partial Nephrectomy. Eur Urol 2019;76:398-403.
    Kim WH; Yoon HK; Jeong CW
    Eur Urol; 2020 Jan; 77(1):e14-e15. PubMed ID: 31586511
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to Johanna Noel, Olivier Huillard, and Francois Goldwasser's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006. Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?
    Mori K; Schmidinger M; Egawa S; Gust KM; Shariat SF
    Eur Urol; 2021 Apr; 79(4):e113-e114. PubMed ID: 33487477
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.